VH4004280

DRUG3 trials

Sponsors

ViiV Healthcare

Conditions

HIV Infections

Phase 1

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants

CompletedNCT05163522

ViiV HealthcareHIV Infections

Start: 2021-12-13End: 2023-06-21Updated: 2025-07-30

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

CompletedNCT06012136

ViiV HealthcareHIV Infections

Start: 2023-08-24End: 2026-06-09Updated: 2026-08-05

Phase 2

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

CompletedNCT06039579

ViiV HealthcareHIV Infections

Start: 2023-10-25End: 2024-06-24Updated: 2025-09-30

Related Papers

Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.

2026-07-29

Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV.

2025-04-262 citations

Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV

Infectious Diseases and Therapy2025-04-022 citations